Literature DB >> 9129028

A histomorphometric comparison of the effects of heparin and low-molecular-weight heparin on cancellous bone in rats.

J M Muir1, J Hirsh, J I Weitz, M Andrew, E Young, S G Shaughnessy.   

Abstract

Long-term heparin treatment causes osteoporosis through, an as yet, undefined mechanism. To investigate this phenomenon and to determine the relative benefits of low-molecular-weight heparin (LMWH) use, we treated rats with once daily subcutaneous injections of either unfractionated heparin (1.0 U/g or 0.5 U/g), the LMWH, Tinzaparin (1.0 U/g or 0.5 U/g), or placebo (saline) for a period of 32 days. The effects on bone were then compared both histomorphometrically and biochemically by measuring urinary type I collagen cross-linked pyridinoline (PYD) and serum alkaline phosphatase, markers of bone resorption and formation, respectively. Histomorphometric analysis of the distal third of the right femur, in the region proximal to the epiphyseal growth plate, demonstrated that both heparin and LMWH decrease cancellous bone volume in a dose-dependent fashion, but that heparin causes significantly more cancellous bone loss than does LMWH. Although both heparin and LMWH decrease osteoblast and osteoid surface to a similar extent, only heparin increases osteoclast surface. In support of these histomorphometric findings, biochemical markers of bone turnover demonstrated that both heparin and LMWH treatment produce a dose-dependent decrease in serum alkaline phosphatase, consistent with reduced bone formation, whereas only heparin causes a transient increase in urinary PYD, consistent with an increase in bone resorption. Based on these observations, we conclude that heparin decreases cancellous bone volume both by decreasing the rate of bone formation and increasing the rate of bone resorption. In contrast, LMWH, causes less osteopenia than heparin because it only decreases the rate of bone formation.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9129028

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  27 in total

1.  VTE, thrombophilia, antithrombotic therapy, and pregnancy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Shannon M Bates; Ian A Greer; Saskia Middeldorp; David L Veenstra; Anne-Marie Prabulos; Per Olav Vandvik
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

2.  Proteoglycans and osteolysis.

Authors:  Marc Baud'Huin; Céline Charrier; Gwenola Bougras; Régis Brion; Frédéric Lezot; Marc Padrines; Dominique Heymann
Journal:  Methods Mol Biol       Date:  2012

Review 3.  Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  David A Garcia; Trevor P Baglin; Jeffrey I Weitz; Meyer Michel Samama
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

4.  Disruption of cell-matrix interactions by heparin enhances mesenchymal progenitor adipocyte differentiation.

Authors:  Weijun Luo; Hailu Shitaye; Michael Friedman; Christina N Bennett; Joshua Miller; Ormond A Macdougald; Kurt D Hankenson
Journal:  Exp Cell Res       Date:  2008-07-12       Impact factor: 3.905

Review 5.  Update on heparin: what do we need to know?

Authors:  Daniel S Weitz; Jeffrey I Weitz
Journal:  J Thromb Thrombolysis       Date:  2010-02       Impact factor: 2.300

6.  A longitudinal study of the effect of heparin thromboprophylaxis during pregnancy on maternal bone metabolism.

Authors:  O Ogueh; M R Johnson; A Benjamin
Journal:  Obstet Med       Date:  2009-11-30

7.  Histopathologic effects of a low molecular weight heparin on bone healing in rats: a promising adjuvant in dacryocystorhinostomy.

Authors:  Mehmet Numan Alp; Ozdamar Fuad Oken; Mustafa Fevzi Sargon; Ahmet Ucaner
Journal:  Int J Ophthalmol       Date:  2016-06-18       Impact factor: 1.779

8.  Inhibition of osteolytic bone metastasis by unfractionated heparin.

Authors:  Colin K Yee; Martin Butcher; Melec Zeadin; Jeffrey I Weitz; Stephen G Shaughnessy
Journal:  Clin Exp Metastasis       Date:  2008-09-24       Impact factor: 5.150

9.  Low-molecular-weight heparin in the treatment of deep venous thrombosis.

Authors:  K E Hauer
Journal:  West J Med       Date:  1998-10

10.  Use of low molecular mass heparin (enoxaparin) in newborn infants: a prospective cohort study of 62 patients.

Authors:  W Streif; G Goebel; A K C Chan; M P Massicotte
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2003-09       Impact factor: 5.747

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.